Transforming the treatment of cancer to improve outcomes.

Oncology Therapeutics

We aim to set new standards of cancer care with our portfolio of oncology therapies.

Coherus is building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved products. We currently have two FDA-approved cancer medicines, LOQTORZI® (toripalimab-tpzi) and UDENYCA®, and we are passionate about developing and commercializing our pipeline of novel, next-generation immuno-oncology treatments that can extend patient survival across tumor types.

The foundation of our immuno-oncology franchise is built upon LOQTORZI, a next-generation PD-1 inhibitor. LOQTORZI is the first and only FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC), and it is in development for the treatment of additional tumor types with the goal of being the PD-1/ICI backbone of future treatment combinations that may extend survival for patients.

We believe improvement in overall survival must come from novel combinations that more broadly target the immune system and particularly mechanisms of PD-1 resistance.

Coherus’ immuno-oncology pipeline includes multiple candidates with differentiated mechanisms targeting the tumor microenvironment that can be used to develop next-generation treatment combinations. Our antibody immunotherapy candidates are focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel anti-IL-27 antibody currently being evaluated in Phase 1/2 clinical trials in lung and liver cancer. CHS-114 is a highly selective, competitively positioned anti-CCR8 cytolytic antibody currently in a Phase 1/2 study as single agent and in combination with toripalimab in patients with advanced solid tumors.

Coherus’ earlier-stage immuno-oncology pipeline targets immune-suppressive mechanisms, including CHS-1000, a preclinical program targeting the novel pathway ILT4 which is expected to enter clinical trials in the second half of 2024. With our immuno-oncology pipeline, we are focusing development efforts on delivering breakthrough survival benefits for cancer patients, beyond the efficacy with existing chemotherapy plus checkpoint inhibitor regimens.

We have multiple novel immuno-oncology programs currently in our development pipeline.